Application for quotation of +securities

Announcement Summary

For personal use only

Entity name

CRESO PHARMA LIMITED

Announcement Type

New announcement

Date of this announcement

Friday January 28, 2022

The +securities to be quoted are:

Other

Total number of +securities to be quoted

ASX +security

Number of +securities to

code

Security description

be quoted

Issue date

CPH

ORDINARY FULLY PAID

1,470,588

28/01/2022

Refer to next page for full details of the announcement

Application for quotation of +securities

1 / 8

Application for quotation of +securities

Part 1 - Entity and announcement details

For personal use only

1.1 Name of entity

CRESO PHARMA LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2

Registered number type

Registration number

ABN

89609406911

1.3

ASX issuer code

CPH

  1. The announcement is New announcement
  2. Date of this announcement

28/1/2022

Application for quotation of +securities

2 / 8

Application for quotation of +securities

Part 2 - Type of Issue

2.1 The +securities to be quoted are: Other

For personal use only

2.2 The +securities to be quoted are:

Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS? No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

The agreement to issue the shares and the issue of shares occurred on the same day. The Company has also lodged an Appendix 2A today for the exercise of 400,000 CPHOA Options into shares, which will not yet be reflected on the issued capital of this Appendix 2A due to limitation in the online forms.

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a +disclosure document or +PDS involving the same class of securities as the +securities to be quoted that meets the requirements of section 708A(11) or 1012DA(11)

Application for quotation of +securities

3 / 8

Application for quotation of +securities

Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an

Appendix 3B

only

Additional +securities to be quoted in an existing class

ASX +security code and description

CPH : ORDINARY FULLY PAID

Issue date

28/1/2022

use

Will the +securities to be quoted rank equally in all respects from their issue date with the

existing issued +securities in that class? Yes

Issue details

For personal

Number of +securities to be quoted

1,470,588

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Issue of 1,470,588 shares to a service provider in lieu of cash fees for investor relations and marketing services.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.085000

Any other information the entity wishes to provide about the +securities to be quoted

N/A

The purpose(s) for which the entity is issuing the securities

To pay for services rendered

Please provide additional details

Issue of 1,470,588 shares to a service provider in lieu of cash fees for investor relations and marketing services.

The Company has also lodged an Appendix 2A today for the exercise of 400,000 CPHOA Options into shares, which will not yet be reflected on the issued capital of this Appendix 2A due to limitation in the online forms.

Application for quotation of +securities

4 / 8

Application for quotation of +securities

For personal use only

Application for quotation of +securities

5 / 8

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Creso Pharma Ltd. published this content on 28 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 January 2022 10:07:27 UTC.